Register Login

Anticoagulant Therapy

New Results on Rivaroxaban

Research data presented Sunday, November 13, 2011 at the American Heart Association Scientific Sessions indicated that adding low doses of Johnson & Johnson and Bayer’s Xarelto (rivaroxaban) to standard antiplatelet therapy significantly prevented the occurrence of secondary cardiovascular events in patients with acute coronary syndrome (ACS), compared with standard therapy alone. The companies plan to seek US […]
read more

NW Medical Lab Symposium Oct 12–15

The Northwest Medical Laboratory Symposium is planned for October 12–15 in the Lynnwood Convention Center, Lynnwood Washington, just north of Seattle. On Friday, October 14, George will speak on “Hemophilia Therapy: From Rasputin to Recombinants,”8:30–10, and “The Top Ten Problems in the Coagulation Laboratory,” 2–3:30. The handouts for these presentations are available for registrants from the NWMLS web site, and are also […]
read more